Understanding the Performance of S&P/NZX50 on July 30, 2020

On July 30, 2020, S&P/NZX50 ended the session in green as the index witnessed a rise of 0.80% to 11,692 while S&P/NZX20 rose by 0.97% to 7,814. On the same day, S&P/NZX10 encountered a rise of 1.21% to 12,391.

S&P/NZX All Consumer Staples ended in green as there was a rise of 2.35% while, on the other hand, S&P/NZX All Energy fell by 1.46%. We would now have a look at the performance of some individual stocks.

On July 30, 2020, the stock price of Ascension Capital Limited (NZX: ACE) rose by 50.00% on an intraday basis to NZ$0.003 per share. On the same day, the share price of Cavalier Corporation Limited (NZX: CAV) increased by 21.88% to NZ$0.390 per share.

The following image provides a broad overview as to how the share price of CAV has trended in the span of past one year:

Stock Performance (Source: NZX)

Stock Performance (Source: NZX)

IKE Ended in Green on July 30, 2020

ikeGPS Group Limited (NZX: IKE) came forward and made an announcement that it has successfully wrapped up institutional placement and institutional entitlement offer. The company stated that new fully paid ordinary shares in IKE offered under institutional placement and institutional entitlement offer are expected to be allotted as well as commence trading on NZX and ASX on August 5, 2020 and would be ranking equally with the existing fully paid ordinary shares.

The company would be raising around NZ$19.7 Mn (A$18.4 Mn) total from placement and entitlement offer supporting recent customer wins, growing sales pipeline, as well as providing capacity for the potential growth opportunities.

A Recent Update by AFT

AFT Pharmaceuticals (NZX: AFT) came forward and made an announcement that it has signed exclusive Maxigesic IV® licensing and supply agreement for Bulgaria, Cyprus, the Czech Republic, Hungary, Romania as well as Slovakia, countries with the combined population of over 53 Mn.

As per the release, agreement is with the Cyprus based multinational pharmaceutical company, Medochemie, which earlier signed a licensing agreement for Maxigesic IV® for Ukraine and 9 countries of Commonwealth of Independent States.

It was also mentioned that Maxigesic IV® regulatory approvals in 6 European countries covered by the agreement are anticipated to conclude in the upcoming few months. Notably, sales are expected in 2021 calendar year.


Disclaimer
The website https://kalkinemedia.com/nz is a service of Kalkine Media New Zealand Limited (Kalkine Media), Company Number: 8107196. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK